A phase III double-blind placebo-controlled trial of methylnaltrexone (MNTX) for opioid-induced constipation (OIC) in advanced medical illness (AMI)

J. Thomas; A. Lipman; N. Slatkin; G. Wilson; M. Moehl; C. Wellman; D. Zhukovsky; R. Stephenson; N. Stambler; R. J. Israel

doi:10.1200/jco.2005.23.16_suppl.lba8003

A phase III double-blind placebo-controlled trial of methylnaltrexone (MNTX) for opioid-induced constipation (OIC) in advanced medical illness (AMI)

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.lba8003 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. LBA8003-LBA8003 ◽

Cited By ~ 11

Author(s):

J. Thomas ◽

A. Lipman ◽

N. Slatkin ◽

G. Wilson ◽

M. Moehl ◽

...

Keyword(s):

Controlled Trial ◽

Phase Iii ◽

Medical Illness ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Patient‐Reported Outcomes and the Association With Clinical Response in Patients With Active Psoriatic Arthritis Treated With Golimumab: Findings Through 2 Years of a Phase III, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial

Arthritis Care & Research ◽

10.1002/acr.22044 ◽

2013 ◽

Vol 65 (10) ◽

pp. 1666-1673 ◽

Cited By ~ 16

Author(s):

Arthur Kavanaugh ◽

Iain B. McInnes ◽

Gerald G. Krueger ◽

Dafna Gladman ◽

Anna Beutler ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Clinical Response ◽

Patient Reported Outcomes ◽

Controlled Trial ◽

Phase Iii ◽

Double Blind ◽

Double Blind Placebo ◽

Patient Reported

Download Full-text

Faculty Opinions recommendation of Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734268130.793576219 ◽

2020 ◽

Author(s):

Pedro Machado

Keyword(s):

Tumor Necrosis ◽

Axial Spondyloarthritis ◽

Controlled Trial ◽

Phase Iii ◽

Inadequate Response ◽

Tumor Necrosis Factor Inhibitors ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Necrosis Factor

Download Full-text

Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group

JAMA ◽

10.1001/jama.271.23.1836 ◽

1994 ◽

Vol 271 (23) ◽

pp. 1836-1843 ◽

Cited By ~ 136

Author(s):

C. J. Fisher

Keyword(s):

Receptor Antagonist ◽

Controlled Trial ◽

Interleukin 1 ◽

Sepsis Syndrome ◽

Phase Iii ◽

Study Group ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 1 Receptor Antagonist ◽

Trial Phase

Download Full-text

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES)

Clinical Colorectal Cancer ◽

10.1016/j.clcc.2016.08.008 ◽

2017 ◽

Vol 16 (2) ◽

pp. 103-114.e3 ◽

Cited By ~ 9

Author(s):

Tamás Pinter ◽

Zandra Klippel ◽

Alvydas Cesas ◽

Adina Croitoru ◽

Jochen Decaestecker ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Controlled Trial ◽

Locally Advanced ◽

Evaluation Study ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

Anti Vegf

Download Full-text

Cariprazine in Negative Symptoms of Schizophrenia: Post-hoc Analyses of a Fixed-dose Phase Iii, Randomized, Double-blind, Placebo- and Active-controlled Trial

European Psychiatry ◽

10.1016/s0924-9338(15)30197-8 ◽

2015 ◽

Vol 30 ◽

pp. 242 ◽

Cited By ~ 4

Author(s):

M. Debelle ◽

S. Faradzs-zade ◽

B. Szatmari ◽

K. Nagy ◽

G. Nemeth ◽

...

Keyword(s):

Negative Symptoms ◽

Controlled Trial ◽

Phase Iii ◽

Fixed Dose ◽

Double Blind ◽

Double Blind Placebo ◽

Post Hoc

Download Full-text

Phase III, randomized, double-blind, placebo-controlled trial of topical 2 % lidocaine for the prevention and treatment of oral mucosal pain in children

Clinical Oral Investigations ◽

10.1007/s00784-013-1063-7 ◽

2013 ◽

Vol 18 (4) ◽

pp. 1189-1194 ◽

Cited By ~ 6

Author(s):

Amélie E Coudert ◽

Agnès Ostertag ◽

Vanessa Baaroun ◽

Catherine Artaud ◽

Chantal Ifi-Naulin ◽

...

Keyword(s):

Controlled Trial ◽

Phase Iii ◽

Double Blind ◽

Double Blind Placebo ◽

Prevention And Treatment

Download Full-text

7119 Genitourinary malignancies – Renal cancer Quality of life (QOL) in treatment-naïve and cytokine-pretreated patients with advanced renal cell carcinoma (RCC) treated with pazopanib: results from a phase III double-blind, placebo-controlled trial

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)71452-1 ◽

2009 ◽

Vol 7 (2) ◽

pp. 428-429 ◽

Cited By ~ 3

Author(s):

R. Hawkins ◽

R. Hodge ◽

M. Chen ◽

M. Neary ◽

A.S. Pickard ◽

...

Keyword(s):

Quality Of Life ◽

Renal Cell Carcinoma ◽

Renal Cell ◽

Controlled Trial ◽

Phase Iii ◽

Double Blind ◽

Double Blind Placebo ◽

Treatment Naïve ◽

Pretreated Patients

Download Full-text

Folic Acid Supplementation in Postmenopausal Women with Hot Flushes: Phase III Randomised Double-Blind Placebo-Controlled Trial

10.22541/au.159560819.90629469 ◽

2020 ◽

Author(s):

Ayman Ewies ◽

Ikhlaq Ahmed ◽

Farook Alazzawi ◽

Joan Pitkin ◽

Pratima Gupta ◽

...

Keyword(s):

Folic Acid ◽

Postmenopausal Women ◽

Controlled Trial ◽

Folic Acid Supplementation ◽

Phase Iii ◽

Hot Flushes ◽

Double Blind ◽

Double Blind Placebo ◽

Acid Supplementation

Download Full-text

Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2018-213032 ◽

2018 ◽

Vol 77 (6) ◽

pp. 883-889 ◽

Cited By ~ 33

Author(s):

Joan T Merrill ◽

William R Shanahan ◽

Morton Scheinberg ◽

Kenneth C Kalunian ◽

David Wofsy ◽

...

Keyword(s):

Systemic Lupus Erythematosus ◽

Lupus Erythematosus ◽

Controlled Trial ◽

Selective Inhibitor ◽

Phase Iii ◽

Systemic Lupus ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

B Cell Activating Factor

Download Full-text

STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC)

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.4006 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 4006-4006 ◽

Cited By ~ 27

Author(s):

Jordi Bruix ◽

Tadatoshi Takayama ◽

Vincenzo Mazzaferro ◽

Gar-Yang Chau ◽

Jiamei Yang ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Controlled Trial ◽

Phase Iii ◽

Double Blind ◽

Double Blind Placebo

Download Full-text